This review addresses the growing field of cardio-oncology, focusing on the cardiotoxic effects of modern cancer therapies. Based on research published in Current Cardiology Reports, the work identifies signaling pathways like Neuregulin-1 that are critical to heart health during chemotherapy.
Effective management requires a comprehensive understanding of how treatments such as Trastuzumab affect cardiac signaling. The Exactitude Medical Foundation advocates for proactive cardiovascular monitoring in cancer survivors to detect ischemic heart disease and cell signaling disruptions before long-term damage occurs.